BridgeBio Pharma, Inc. Increase (Decrease) in Employee Related Liabilities
BridgeBio Pharma, Inc. (BBIO) reported Increase (Decrease) in Employee Related Liabilities of -$25.75 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities · last filed 2026-08-10
- BridgeBio Pharma, Inc. increase (decrease) in employee related liabilities for the quarter ending 2026-06-30 was $11.72M, a 214.57% increase year-over-year.
- BridgeBio Pharma, Inc. increase (decrease) in employee related liabilities for the quarter ending 2026-03-31 was -$37.48M.
- BridgeBio Pharma, Inc. increase (decrease) in employee related liabilities for the quarter ending 2025-12-31 was $19.81M, a 73.68% increase year-over-year.
- BridgeBio Pharma, Inc. increase (decrease) in employee related liabilities for the quarter ending 2025-09-30 was $18.85M, a 35.04% increase year-over-year.
- BridgeBio Pharma, Inc. increase (decrease) in employee related liabilities for fiscal 2025 was $23.02M, a 35.54% increase from fiscal 2024.
- BridgeBio Pharma, Inc. increase (decrease) in employee related liabilities for fiscal 2024 was $16.99M, a 117.71% increase from fiscal 2023.
- BridgeBio Pharma, Inc. increase (decrease) in employee related liabilities for fiscal 2023 was $7.80M.
- BridgeBio Pharma, Inc. increase (decrease) in employee related liabilities for fiscal 2022 was -$2.36M, a 132.01% decline from fiscal 2021.
| Period end | Increase (Decrease) in Employee Related Liabilities 3 month | Increase (Decrease) in Employee Related Liabilities 6 month | Increase (Decrease) in Employee Related Liabilities 9 month | Increase (Decrease) in Employee Related Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$25.75M 10-Q · filed 2026-08-10 | -$5.95M derived: sum of 3 quarters · filed 2026-08-10 | $12.90M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$37.48M 10-Q · filed 2026-05-07 | -$17.67M derived: sum of 2 quarters · filed 2026-05-07 | $1.18M derived: sum of 3 quarters · filed 2026-05-07 | $4.91M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $19.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $38.66M derived: sum of 2 quarters · filed 2026-02-24 | $42.38M derived: sum of 3 quarters · filed 2026-08-10 | $23.02M 10-K · filed 2026-02-24 |
| 2025-09-30 | $18.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $22.57M derived: sum of 2 quarters · filed 2026-08-10 | $3.21M 10-Q · filed 2025-10-29 | $14.62M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $3.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$15.64M 10-Q · filed 2026-08-10 | -$4.23M derived: sum of 3 quarters · filed 2026-08-10 | $9.73M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$19.36M 10-Q · filed 2026-05-07 | -$7.96M derived: sum of 2 quarters · filed 2026-05-07 | $6.00M derived: sum of 3 quarters · filed 2026-05-07 | $12.59M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $11.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $25.36M derived: sum of 2 quarters · filed 2026-02-24 | $31.95M derived: sum of 3 quarters · filed 2026-02-24 | $16.99M 10-K · filed 2026-02-24 |
| 2024-09-30 | $13.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $20.55M derived: sum of 2 quarters · filed 2025-10-29 | $5.58M 10-Q · filed 2025-10-29 | $17.54M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $6.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$8.38M 10-Q · filed 2025-08-05 | $3.58M derived: sum of 3 quarters · filed 2026-02-24 | $10.49M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$14.97M 10-Q · filed 2025-04-29 | -$3.01M derived: sum of 2 quarters · filed 2026-02-24 | $3.90M derived: sum of 3 quarters · filed 2026-02-24 | $11.20M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $11.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $18.87M derived: sum of 2 quarters · filed 2026-02-24 | $26.17M derived: sum of 3 quarters · filed 2026-02-24 | $7.80M 10-K · filed 2026-02-24 |
| 2023-09-30 | $6.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $14.21M derived: sum of 2 quarters · filed 2024-11-12 | -$4.16M 10-Q · filed 2024-11-12 | $2.60M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $7.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$11.07M 10-Q · filed 2024-08-01 | -$4.31M derived: sum of 3 quarters · filed 2025-02-20 | -$4.03M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | -$18.37M 10-Q · filed 2024-05-02 | -$11.61M derived: sum of 2 quarters · filed 2025-02-20 | -$11.33M derived: sum of 3 quarters · filed 2025-02-20 | -$3.85M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $6.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $7.04M derived: sum of 2 quarters · filed 2025-02-20 | $14.51M derived: sum of 3 quarters · filed 2025-02-20 | -$2.36M 10-K · filed 2025-02-20 |
| 2022-09-30 | $280.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $7.75M derived: sum of 2 quarters · filed 2023-11-02 | -$9.12M 10-Q · filed 2023-11-02 | $2.70M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $7.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$9.40M 10-Q · filed 2023-08-03 | $2.42M derived: sum of 3 quarters · filed 2024-02-22 | $6.47M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$16.88M 10-Q · filed 2023-05-04 | -$5.05M derived: sum of 2 quarters · filed 2024-02-22 | -$1.00M derived: sum of 3 quarters · filed 2024-02-22 | $3.48M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $11.82M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $15.87M derived: sum of 2 quarters · filed 2024-02-22 | $20.36M derived: sum of 3 quarters · filed 2024-02-22 | $7.38M 10-K · filed 2024-02-22 |
| 2021-09-30 | $4.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $8.54M derived: sum of 2 quarters · filed 2022-11-03 | -$4.44M 10-Q · filed 2022-11-03 | $1.75M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $4.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$8.49M 10-Q · filed 2022-08-04 | -$2.30M derived: sum of 3 quarters · filed 2023-02-23 | $2.15M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | -$12.98M 10-Q · filed 2022-05-05 | -$6.79M derived: sum of 2 quarters · filed 2023-02-23 | -$2.34M derived: sum of 3 quarters · filed 2023-02-23 | $3.28M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $6.19M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $10.64M derived: sum of 2 quarters · filed 2023-02-23 | $16.26M derived: sum of 3 quarters · filed 2023-02-23 | $8.59M 10-K · filed 2023-02-23 |
| 2020-09-30 | $4.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $10.06M derived: sum of 2 quarters · filed 2021-11-04 | $2.40M 10-Q · filed 2021-11-04 | $8.13M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $5.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$2.05M 10-Q · filed 2021-08-05 | $3.69M derived: sum of 3 quarters · filed 2022-02-25 | $6.53M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | -$7.67M 10-Q · filed 2021-05-06 | -$1.93M derived: sum of 2 quarters · filed 2022-02-25 | $911.00K derived: sum of 3 quarters · filed 2022-02-25 | $2.03M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $5.74M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $8.58M derived: sum of 2 quarters · filed 2022-02-25 | $9.70M derived: sum of 3 quarters · filed 2022-02-25 | $9.27M 10-K · filed 2022-02-25 |
| 2019-09-30 | $2.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $3.96M derived: sum of 2 quarters · filed 2020-11-05 | $3.53M 10-Q · filed 2020-11-05 | $4.56M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $1.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $689.00K 10-Q · filed 2020-08-11 | $1.72M derived: sum of 3 quarters · filed 2021-02-25 | |
| 2019-03-31 | -$432.00K 10-Q · filed 2020-05-14 | $595.00K derived: sum of 2 quarters · filed 2021-02-25 | ||
| 2018-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $3.40M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $2.37M 10-Q · filed 2019-11-08 | |||
| 2017-12-31 | $1.13M 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |